skip to content »

diabetes-endocrinology

Houston, Texas

Anatomy instruction at Baylor College of Medicine
Medicine/Endocrinology
not shown on screen

Alan J. Garber, M.D., Ph.D.

photo of Alan J. Garber, M.D., Ph.D.Professor of Medicine, Biochemistry & Molecular Biology, and Molecular & Cellular Biology Division of Diabetes, Endocrinology & Metabolism

Contact Information

Baylor College of Medicine
1709 Dryden, Suite 1000
Houston, TX 77030
Tel: 713-798-0230
Fax: 713-798-2750

Education

M.D.: Temple University, Philadelphia, Pa.
Residency: Internal Medicine, Temple University Hospital
Fellowship: Metabolism, Barnes Hospital, St. Louis, Mo.

Research Interests

  • Diabetes
  • Dyslipidemias
  • Metabolic Syndrome
  • Atherosclerosis

Recent Publications

  1. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Garber AJ; INITIATE Study Group. (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005 Feb;28(2):260-5.
  2. Bryer-Ash M, Garber AJ. (2005). Point: Inpatient glucose control: the emperor finally has clothes. Diabetes Care. 2005 Apr;28(4):973-5.
  3. Garber AJ, ed. (2005) Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. Am J of Med, April 2005 (Vol 118, Suppl 2).
  4. Vasudevan AR, Garber AJ (2005). Insulin resistance syndrome: a review. Minerva Endocrinologica 2005;30:101-119.
  5. Garber AJ, Johnson DL, Krauss MD, et al (2005). Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. Proceedings summary from a World Federation for Mental Health meeting, Sept 29-30, 2004;Vienna, Austria. J Clin Psychiatry 2005;66:790-798.
  6. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E and Jain R, for the 1-2-3 Study Group (2005). Attainment of glycemic goals in type 2 diabetes with once-, twice-, or three-times-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 Study). Diabetes, Obesity and Metabolism, 2005 Dec 8;(1)58-66.
  7. Garber AJ (2005). Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management. Diabetes, Obesity and Metabolism. 2005 Nov;7(6)666-674.
  8. Garber AJ (2006). Use of premixed insulin analogs in the treatment of diabetes. Drugs, 2006;66(1):31-49.
  9. Gotto, Jr AM, Blackburn GL, Dailey GE, Garber AJ, et al (2006). The metabolic syndrome: a call to action. Coronary Artery Disease, 2006. Feb 17(1):77-80.
  10. Vasudevan AR and Garber AJ (2006). Diabetic dyslipidemia and the heart. Heart Failure Clinics, 2006 Jan;2(1):37-52.
  11. Garber AJ, Klein E, Bruce S, Sankoh S and Mohideen P (2006). Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes, Obesity and Metabolism, 2006 March;8(2)156-163.
  12. Garber AJ, et al. (2006) American College of Endocrinology Position Statement on Inpatient Diabetes and Glycemic Control. ACE Task Force. Endocrine Practice 2006;12(Suppl 1):6-12.
  13. AACE Online: http://www.aace.com/meetings/consensus/IIDC/IDGC0207.pdf.
  14. Garber AJ, et al. (2006) American Association of Clinical Endocrinologists, American College of Endocrinology, and the American Diabetes Association Position Statement on Inpatient Diabetes and Glycemic Control. AACE/ACE/ADA Task Force on Inpatient Diabetes. Diabetes Care 2006;29:1955-1962.
  15. Rosenstock J, Rood J, Cobitz A, Huang C and Garber AJ (2006). Improvement in glycemic control with rosiglitazone/metformin fixed dose combination therapy in patients with type 2 diabetes with very poor glycemic control. Diabetes, Obesity and Metabolism, 2006 Nov;8(6)643-649.
  16. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H and Garber AJ (2006). Initial treatment with rosiglitazone/metformin fixed dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2006 Nov;8(6)650-660.
  17. Garber AJ, Ligthelm R, Christiansen JC and Liebl A (2007). Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism, 9, 2007, 630-639.
  18. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. (2007). Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes, Obesity and Metabolism. 2007 Mar;9(2):166-74.
  19. Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, and Garber AJ, on behalf of the INITIATE Study Group (2007). Basal insulin or premix analogue therapy in type 2 diabetes patients. European Journal of Internal Medicine 2007;18:56-62.
  20. Bosi E, Camisasca RP, Collober C, Rochotte E, and Garber AJ (2007). Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, published online on February 2, 2007 as 10.2337/dc06-1732.
  21. Garber AJ, Clauson P, Pedersen CB, and Kolendorf K (2007). Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase 3 trials. J Am Geriatr Soc. 2007 Nov;55(11)1735-40.
  22. Davidson MH, Basile J, Garber AJ, Phillips RA. (2007) Reducing the risk of stroke through appropriate targets and treatments. Prev Cardiol. 2007 Fall;10(4):215-21.
  23. Garber AJ, Sharma MD (2008). Update: vildagliptin for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2008 Jan;17(1):105-113.

E-mail this page to a friend